Long Term Antipsychotic Treatment and Brain Volumes: a longitudinal study of first episode schizophrenia studyhttp://archpsyc.jamanetwork.com/article.aspx?articleid=211084
Arch Gen Psychiatry. 2011;68(2):128-137.
doi:10.1001/archgenpsychiatry.2010.199
The Myth of Schizophrenia as a Progressive Brain Disease
http://schizophreniabulletin.oxfordjournals.org/content/39/6/1363
Factors Involved in Outcome and Recovery in Schizophrenia Patients Not on Antipsychotic Medications:
A 15-Year Multifollow-Up Study
http://psychrights.org/research/digest/nlps/OutcomeFactors.pdf
It's all done with smoke and mirrors. Or, how to create the illusion of a schizophrenic brain disease
Reprinted from Clinical Psychology Issue 12. April 2002 pp 9-16
http://www.critpsynet.freeuk.com/Boyle.htm
category: Community Treatment Orders
The Lancet
The Lancet, Early Online Publication, 26 March 2013doi:10.1016/S0140-6736(13)60107-5Cite or Link Using DOI This article can be found in the following collections:
Psychiatry (Schizophrenia)Community treatment orders for patients with psychosis (OCTET): a randomised controlled trial
Prof Tom Burns DSc a , Jorun Rugkåsa PhD a d, Andrew Molodynski MBChB e, John Dawson LLD f, Ksenija Yeeles BSc a, Maria Vazquez-Montes PhD b, Merryn Voysey MBiostat c, Julia Sinclair DPhil g, Prof Stefan Priebe FRCPsych h
Background
Compulsory supervision outside hospital has been developed internationally for the treatment of mentally ill people following widespread deinstitutionalisation but its efficacy has not yet been proven. Community treatment orders (CTOs) for psychiatric patients became available in England and Wales in 2008. We tested whether CTOs reduce admissions compared with use of Section 17 leave when patients in both groups receive equivalent levels of clinical contact but different lengths of compulsory supervision.
Complete Lancet article available at http://www.sciencedirect.com/science/article/pii/S0140673613601075
This is the third, and largest, randomised trial of CTOs, and, similar to its predecessors, did not find any evidence that CTOs achieve their intended purpose of reducing readmission in so-called revolving door patients with a diagnosis of psychosis. The evidence is now strong that the use of CTOs does not confer early patient benefits despite substantial curtailment of individual freedoms. In view of the now consistent experimental evidence against any clear benefit, we believe any proposal to either introduce CTOs to new jurisdictions or extend their use would require a commitment to test their effects at least as rigorously as we have done. Major ethical and legal barriers have to be overcome to do such research.7, 20 and 21 International experience indicates that clinicians rapidly form strong opinions for or against CTOs and clinical equipoise is soon lost.22 However, as previously argued, the introduction of such restrictions on patient liberties would be unethical unless accompanied by a rigorous assessment of their potential costs and benefits.23
Category: Prescription drugs
Prescription Drugs Associated with Reports of Violence towards Others
Thomas J. Moore, Joseph Glenmullen, Curt D. Furberg
Conclusions
Acts of violence towards others are a genuine and serious adverse drug event associated with a relatively small group of drugs. Varenicline, which increases the availability of dopamine, and antidepressants with serotonergic effects were the most strongly and consistently implicated drugs. Prospective studies to evaluate systematically this side effect are needed to establish the incidence, confirm differences among drugs and identify additional common features.
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0015337?
Category: Placebo
Meta-Regression Analysis of Placebo
Response in Antipsychotic Trials, 1970–2010
Am J Psychiatry 2013;170:1335-1344.
doi:10.1176/appi.ajp.2013.12030315
http://ajp.psychiatryonline.org/article.aspx?articleID=1722041Category: Stigma
Does the disease view of mental disorder reduce stigma?
Mehta S., Farina, A, Journal of social and clinical psychology ISSN 0736-7236 CODEN JSCPFF
1997, vol. 16, no4, pp. 405-419 (2 p.1/4)
Evolution of public attitudes about mental illness: a systematic review and meta-analysis
G. Schomerus1, C. Schwahn2, A. Holzinger3, P. W. Corrigan4, H. J. Grabe1, M. G. Carta5, M. C. Angermeyer5,6Article first published online: 13 JAN 2012
Acta Psychiatrica Scandinavica
DOI: 10.1111/j.1600-0447.2012.01826.xhttp://onlinelibrary.wiley.com/doi/10.1111/j.1600-0447.2012.01826.x/abstract
Brett J. Deacon and Grayson L. Baird (2009). The Chemical
Imbalance Explanation of Depression: Reducing Blame at What Cost? Journal of Social and Clinical
Psychology: Vol. 28, No. 4, pp. 415-435.
doi: 10.1521/jscp.2009.28.4.415
The Chemical Imbalance Explanation of Depression: Reducing Blame at What Cost?
Journal of Clinical and Social Psychology, 28, 415–435.
Brett J. Deacon, Grayson L. Baird
University of Wyoming
Compared to the biopsychosocial model, the chemical imbalance model was associated with significantly less self-stigma but also significantly lower credibility, a worse expected prognosis, and the perception that psychosocial interventions would be ineffective. The chemical imbalance explanation appears to reduce blame at the cost of fostering pessimism about recovery and the efficacy of nonbiological treatments.
http://guilfordjournals.com/doi/abs/10.1521/jscp.2009.28.4.415
Read More: http://guilfordjournals.com/doi/abs/10.1521/jscp.2009.28.4.415
Category: Heritability/Genetics
News Release No. 13-33: American Psychiatric Association, May 3, 2013
Statement by David Kupfer, MD
Chair of DSM-5 Task Force Discusses Future of Mental Health Research
The promise of the science of mental disorders is great. In the future, we hope to be able to identify disorders using biological and genetic markers that provide precise diagnoses that can be delivered with complete reliability and validity. Yet this promise, which we have anticipated since the 1970s, remains disappointingly distant. We’ve been telling patients for several decades that we are waiting for biomarkers. We’re still waiting. In the absence of such major discoveries, it is clinical experience and evidence, as well as growing empirical research, that have advanced our understanding of disorders such as autism spectrum disorder, bipolar disorder, and schizophrenia.
Category: Heritability/Genetics
News Release No. 13-33: American Psychiatric Association, May 3, 2013
Statement by David Kupfer, MD
Chair of DSM-5 Task Force Discusses Future of Mental Health Research
The promise of the science of mental disorders is great. In the future, we hope to be able to identify disorders using biological and genetic markers that provide precise diagnoses that can be delivered with complete reliability and validity. Yet this promise, which we have anticipated since the 1970s, remains disappointingly distant. We’ve been telling patients for several decades that we are waiting for biomarkers. We’re still waiting. In the absence of such major discoveries, it is clinical experience and evidence, as well as growing empirical research, that have advanced our understanding of disorders such as autism spectrum disorder, bipolar disorder, and schizophrenia.
Posts
No comments:
Post a Comment
I am no longer approving comments. All I ask is that you be respectful of others and refrain from using profanity.